50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Biologic Therapies for NHL (Excluding Pre-clinical Models) Poster III

Monday, December 8, 2008: 5:30 PM-7:30 PM

Hall A (Moscone Center)

A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Michelle A. Fanale, M.D.¹, Luis E. Fayad, M.D.¹, Barbara Pro, M.D.¹, Felipe Samaniego, M.D.¹^*, Gracy Zachariah, R.N.²^*, Cesar A. Nunez, M.D.³^*, Yuan Ji, Ph.D.⁴^* and Anas Younes, M.D.¹^*

¹Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX
²Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
³Department of Pediatrics, University of Texas M.D. Anderson Cancer Center, Houston, TX
⁴Department of Bioinformatics and Computational Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX

3049

The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial

Eva Hoster¹^*, Michael Unterhalt, PhD²^*, Bernhard Wörmann³^*, Ulrich Dührsen⁴^*, Bernd Metzner⁵, Hartmut Eimermacher⁶^*, Andreas Neubauer⁷, Hannes Wandt⁸^*, Hjalmar Steinhauer⁹^*, Sonja Martin¹⁰^*, Else Heidemann¹¹^*, Ali Aldaoud¹²^*, Wolfgang Hiddemann¹ and Martin Dreyling¹³

¹University of Munich, Munich, Germany
²Department of Internal Medicine III, University of Munich-Hospital Großhadern, Munich, Germany
³Municipal Medical Center, Braunschweig, Germany
⁴University Hospital, Essen, Germany
⁵Klinikum Oldenburg, Oldenburg, Germany
⁶St. Marien Hospital, Hagen, Germany
⁷Philipps University, Marburg, Germany
⁸Klinikum Nuernberg Nord, Nuernberg, Germany
⁹Carl-Thiem-Klinikum, Cottbus, Germany
¹⁰Robert-Bosch-Krankenhaus, Stuttgart
¹¹Diakonissen-Krankenhaus, Stuttgart, Germany
¹²Praxis für Haematologie / Onkologie, Leipzig
¹³Department of Internal Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany

3050

Rituximab Plus Hypercvad Alternating with High Dose Methotrexate and Cytarabine for Patients with Newly Diagnosed Mantle Cell Lymphoma. A Multicenter Trial from GISL

Francesco Merli¹^*, Stefano Luminari²^*, Fiorella Ilariucci³^*, Caterina Stelitano²^*, Mario Petrini²^*, Nicola Di Renzo²^*, Francesco Angrilli²^*, Angelo Michele Carella²^*, Elisa Barbolini³^* and Massimo Federico²^*

¹Hematology, AO "S.Maria Nuova", Reggio Emilia, Italy
²Gruppo Italiano Studio Linfomi, Italy
³Hematology, AO "S.M. Nuova", Reggio Emilia, Italy

3051

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Jorge Romaguera, MD¹, Luis Fayad¹, Peter McLaughlin, MD¹^*, Barbara Pro, MD¹, Maria Alma Rodriguez, MD¹, Michael Wang, MD¹^*, Pamela Weaver, RN¹^*, Kimberly Hartig¹^*, Larry Kwak, MD, PhD¹^*, Tatyana Feldman, MD², Judy Smith, RN²^*, Peggy Ford, RN²^*, Stuart Goldberg, MD²^*, Andrew Pecora, MD²^* and Andre Goy, MD²^*

¹Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX
²Department of Lymphoma, Hackensack University Medical Center, Hackensack, NJ

3052

Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin Lymphoma

John Kuruvilla, MD¹, Diane Taylor²^*, Lisa Wang³^*, Chantale Blattler⁴^*, Armand Keating, MD⁵ and Michael Crump, MD⁶

¹Lymphoma Program, The Princess Margaret Hospital, Toronto, ON, Canada
²The Princess Margaret Hospital, Toronto, ON, Canada
³Clinical Study Coordination and Biostatistics, The Princess Margaret Hospital, Toronto, ON, Canada
⁴Drug Development Program, The Princess Margaret Hospital, Toronto, ON, Canada
⁵Princess Margaret Hospital, Toronto, ON, Canada
⁶Lymphoma Program, Princess Margaret Hospital, Toronto, ON, Canada

3053

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Robert A. Baiocchi^*, Lapo Alinari^*, Thomas S. Lin^*, Pierluigi Porcu^*, Jeffrey Jones^*, Joseph Flynn^*, William Hicks^*, Margaret S. Lucas^*, Lai Wei^*, Jeffrey S. Johnston^* and John C. Byrd^*

Division of Hematology/Oncology, Ohio State University, Columbus, OH

3054

A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection

Roberto Guariglia¹^*, Stefano Luminari²^*, Amalia De Renzo²^*, Emilio Iannitto²^*, Matteo Dell'Olio²^*, Samantha Pozzi²^*, Teresa Pierri³^*, Lucia D'Amato⁴^*, Antonio Traficante⁴^*, Stefano Sacchi²^* and Pellegrino Musto¹

¹Hematology and Stem Cell Transplantation, IRCCS - CROB, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (Pz), Italy
²GISL, Gruppo Italiano Studio Linfomi, Modena
³Transfusion Service, S. Carlo Hospital, Potenza, Italy
⁴Central Laboratory, IRCCS - CROB, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture (Pz), Italy

3055

Radioimmunotherapy (RIT) with ¹⁷⁷ Lutetium-DOTA-Rituximab (¹⁷⁷LU-D-R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

Andreas Lohri, MD¹, Flavio Forrer, MD, PhD²^*, Benedetta Campana¹^*, Christoph Mamot, MD³^*, Ralph Winterhalder, MD⁴^*, Richard Herrmann, MD³^*, Helmuth R Maecke, PhD⁵^* and Jan Müller-Brand, MD²^*

¹Dept. of Oncology/Hematology, Medical University Clinic, Liestal, Switzerland
²Dept. of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
³Medical Oncology, University Hospital Basel, Basel, Switzerland
⁴Department of Medical Oncology, Kantonsspital, Lucerne, Switzerland
⁵Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland

3056

R-FND Followed by Radioimmunotherapy for High-Risk Follicular Lymphoma

Peter McLaughlin, MD¹^*, Sattva Neelapu, MD¹^*, Michelle Fanale, MD¹^*, Maria Rodriguez, MD¹^*, Ana Ayala, RN²^*, Barbara Pro, M.D.³, F.B. Hagemeister²^*, Anas Younes²^*, Susan Neel²^*, Nathan Fowler²^*, Mark Hess²^* and Larry W. Kwak²^*

¹M.D. Anderson Cancer Center, University of Texas, Houston, TX
²Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX
³Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX

3057

Long Term Responses to Fludarabine and Rituximab in Waldenstrom's Macroglobulinemia

Steven Treon, MD, PhD¹, Andrew Branagan¹^*, Leukothea Ioakimidis, PhD²^*, Jacob Soumerai³^*, Christopher Patterson, MD⁴^*, Parveen Wasi, MD, FRCP(C)⁵, Christos Emmanouilides, MD, PhD⁶^*, Stanley R. Frankel, MD⁷, T. Andrew Lister, MD⁸^*, Pierre Morel, MD⁹, Jeffrey Matous, MD¹⁰, Stephanie A. Gregory, MD¹¹^* and Eva K. Kimby, MD, PhD¹²

¹Dana-Farber Cancer Institute, Boston, MA
²Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Dana Farber Cancer Institute, Boston, MA
⁵McMaster University, Hamilton, ON, Canada
⁶Interbalkan Hospital, Pylaia, Greece
⁷Hoffmann-La Roche, Inc, Nutley, NJ
⁸Centre for Medical Oncology, London, United Kingdom
⁹Service d'Hematologie Clinique, Lens, France
¹⁰Rocky Mountain Cancer Center, Denver, CO
¹¹Hematology, Rush University Hospital, Chicago, IL
¹²Hematology Center, Karolinska Institute, Stockholm, Sweden

3058

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD¹, Liang Zhang, PhD¹^*, Luis Fayad, MD¹, Fredrick Hagemeister, MD¹, Sattva Neelapu, MD¹, Felipe Samaniego, M.D.², Barbara Pro, MD¹, Anas Younes, MD¹, Scott Miller³^*, Robert D. Knight, MD³, Jerome B. Zeldis, MD³, Qing Yi, MD, PhD¹ and Jorge Romaguera, MD¹

¹Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX
²Lymphoma/Myeloma, M. D. Anderson Cancer Center, Houston, TX
³Celgene Corporation, Summit, NJ

3059

Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin’s Lymphoma: Feasibility and Initial Safety

Heather A. Jacene¹^*, Yvette L. Kasamon², Richard F. Ambinder², Wayne Kasecamp¹^*, Donna Serena¹^* and Richard L. Wahl¹^*

¹Nuclear Medicine, Johns Hopkins University, Baltimore, MD
²Johns Hopkins University, Baltimore, MD

3060

R²: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL)

Ian DeRook, MD¹^*, Robert T Odonnell, MD, PhD¹^*, B. Noble²^*, C. Quirch²^* and Joseph Tuscano, MD²

¹Internal Medicine, UC Davis Cancer Center, Sacramento, CA
²Hematology - Oncology, UC Davis Medical Center, Sacramento, CA

3061

⁹⁰y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group

A. M. Carella¹, S. Nati¹^*, G. Fraternali Orcioni¹^*, M. Petrini²^*, S. Galimberti²^*, U. Vitolo³^*, N. Cascavilla⁴^* and P.L. Zinzani⁵^*

¹Azienda Ospedaliera Universitaria San Martino, Division of Hematology, Genova, Italy
²Ospedale S. Chiara, Division of Hematology, Pisa, Italy
³Azienda Ospedaliera San Giovanni Battista, Division of Hematology, Torino, Italy
⁴Casa Sollievo della Sofferenza, Division of Hematology, San Giovanni Rotondo, Italy
⁵Department of Hematology/Oncology, Policlinico Sant'Orsola - Malpighi, Bologna, Italy

3062

A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type

Andres JM Ferreri, MD, Giuseppina Patrizia Dognini, M.D.^*, Roberto Crocchiolo, M.D.^*, Silvia Govi, M.D.^*, Giada Licata, M.D.^*, Maurilio Ponzoni, M.D.^*, Antonio Giordano Resti, M.D.^*, Letterio Salvatore Politi, M.D.^*, Alberto Rosso, M.D.^* and Eugenio Villa, M.D.^*

Unit of Lymphoid Malignancies, Department of Oncology, Istituto Scientifico San Raffaele, Milano, Italy

3063

Efficacy of ⁹⁰ Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma

Anna Vanazzi¹^*, Pier Francesco Ferrucci²^*, Chiara Maria Grana³^*, Giancarlo Pruneri⁴^*, Cristiano Crosta⁵^*, Antonello Pinto⁶^*, Marco Chinol³^*, Liliana Calabrese¹^*, Giovanni Paganelli³^* and Giovanni Martinelli¹

¹Hematoncology, European Institute of Oncology, Milano, Italy
²Melanoma and Sarcoma, European Institute of Oncology, Milano, Italy
³Nuclear Medicine, European Institute of Oncology, Milano, Italy
⁴Pathology, European Institute of Oncology, Milano, Italy
⁵Endoscopy, European Institute of Oncology, Milano, Italy
⁶Hematoncology, Istituto Nazionale Tumori De Pascale, Napoli, Italy

3064

Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B- Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network

Karin Hohloch, MD¹^*, P.L. Zinzani, M.D.²^*, Werner Linkesch Jr.³^*, Andrzej Deptala, MD, PhD⁴, Jurczak Wojciech⁵^*, Cheolwon Suh⁶, Michael Lorsbach⁷^*, Christiane Windemuth-Kiesselbach⁷^* and Lorenz H. Truemper⁸

¹Hematology and Oncology, Georg August University, Goettingen, Göttingen, Germany
²Department of Hematology/Oncology, University of Bologna, Bologna, Italy
³Department of Hematology & Stem Cell Transplantation, Medical University of Graz, Graz, Austria
⁴Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland
⁵Haematology /Oncoclogy, University of Krakau, Krakau, Poland
⁶Asan Medical Center, Seoul
⁷Alcedis GmbH, Giessen
⁸Dept. of Hem. and Onc., Georg August University, Gottingen, Germany

3065

Incidence of Transformation to Large Cell Lymphoma and to Second Malignancies in Symptomatic Patients with Waldenstrom's Macroglobulinemia (WM) Treated with Cladribine (2-CdA) Combination Induction Therapy

Ronjay Rakkhit, MD¹^*, Kay B Delasalle, B.S.²^*, Maria B. Gavino, R.N.²^*, Sheeba K. Thomas²^*, Meletios A Dimopoulos, MD³, Fredrick B. Hagemeister, MD², Maria Alma Rodriguez, MD², Peter McLaughlin, MD²^*, Raymond Alexanian, MD² and Donna M. Weber, MD²^*

¹Hematology/Oncology, MD Anderson Cancer Ctr., Houston, TX
²Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX
³Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

3066

Evaluation of Humoral Immune Responses to Vaccination with Tetanus Toxoid and KLH in Rituximab-Treated Follicular Non-Hodgkin’s Lymphoma Patients Compared to Healthy Volunteers

M. Wayne Saville, MD, FACP, FRCPA¹, Nancy Valente, MD², Rachelle Perea¹^*, Kye Gilder¹^*, Judith Berlfein¹^*, Ilya Zyuzgin, PhD³^*, David Belada, MD, PhD.⁴^*, Andre Banat, MD, MBA⁵^* and Tudor Ciuleanu, MD⁶^*

¹Biogen Idec Inc., San Diego, CA
²Genentech, South San Francisco, CA
³Haematology Department #2, Leningrad Regional Clinical Hospital, Saint-Petersburg, Russia
⁴Department of Clinical Hematology, University Hospital Hradec Kralove, Hradec Králové, Czech Republic
⁵Kerckhoff Clinic, University of Giessen, Giessen, Germany
⁶Institutul Oncologic - Universitatea de Medicina, Cluj-Napoca, Romania

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH